KIKentaro Iwaki

Kentaro Iwaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kentaro Iwaki has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 19 September 2009
      • Vol. 56  (93) , 1194-8

    Ampullary cancer and preoperative jaundice: possible indication of the minimal surgery.

    by Hiroki Uchida, Kohei Shibata, Kentaro Iwaki, Seiichiro Kai, Masayuki Ohta, Seigo Kitano

    Obstructive jaundice is common symptom of carcinoma of the ampulla of Vater. In the present study we evaluated association between preoperative jaundice and prognosis and possible indication of the minimal surgery. Clinicopathological features of 50 patients who underwent curative resection were examined retrospectively and statistically analyzed. Thirty-two of the 50 patients (64%) had preoperative jaundice, and these patients had poorer survival compared with these without jaundice (5 year survival 57.2% vs. 100%, p < 0.01). Preoperative jaundice, serum carbohydrate antigen 19-9 level, pancreatic invasion, lymphatic invasion, venous invasion, perineural invasion, duodenal invasion, margin status, lymph node metastasis, and T stage were shown to be significant prognostic factors. In the 18 patients without preoperative jaundice, lymphatic invasion was significantly related to lymph node metastasis. In addition, 12 of the 14 patients without jaundice and lymphatic invasion were diagnosed as T1N0 (stage IA) disease, and all the tumors were papillary or well-differentiated adenocarcinoma. Preoperative jaundice may reflect advanced-stage in case of ampullary cancer. Radical surgery may not be necessary in patients without preoperative jaundice if the tumor is diagnosed as a papillary or well-differentiated adenocarcinoma without lymphatic invasion.


  • Weight Loss and Improvement of Comorbidities after Laparoscopic Adjustable Gastric Banding for Morbid Obesity

    by Masayuki Ohta, Seigo Kitano, Seiichiro Kai, Yuichi Endo, Hidetoshi Eguchi, Ryoki Okunaga, Hiroki Uchida, Kentaro Iwaki, Kohei Shibata

    はじめに: 我々が我が国に導入した腹腔鏡下調節性胃バンディング術 (laparoscopic adjustable gastric banding; 以下, LAGB) の体重減少効果と肥満関連健康障害に対する改善効果について検討したので報告する. 方法: 2005年8月からの2年間に21例の内科治療無効の肥満症例にLAGBを施行した. 平均年齢38歳, BMI 44kg/m2であり, 肥満関連健康障害を平均3.1疾患有していた. LAGBは全例, Pars flaccida法で行い, バンドの逸脱予防のために胃-胃縫合を3~5針行った. 結果 LAGBの周術期に1例も合併症を認めず, 術後の平均在院期間は平均3.4日であった. LAGB後の平均体重減少は12か月25kg, 18か月29kgであり, 過剰体重減少率は12か月41%, 18か月49%であった. 良好な体重減少により, 高血圧91%, 高脂血症94%, 糖尿病100%と高率に改善した. 考察: LAGBは安全性と有効性を兼ね備えた術式であり, 今後我が国においても普及していくものと思われた.


  • A Case of Granulomatous Abscess of the Liver detected by 18F-fluorodeoxyglucose Positron Emission Tomography which is Very Difficult to Differ from Cholangiocellular Carcinoma

    by Takashi Masuda, Hiroki Uchida, Kentaro Iwaki, Hidetoshi Eguchi, Yuichi Endo, Yoshiki Okunaga, Seiichiro Kai, Kohei Shibata, Masayuki Ohta, Seigo Kitano

    症例は53歳の女性で, 健診の18F-fluorodeoxyglucose positron emission tomographyにて肝外側区域に異常集積を示す腫瘍性病変を指摘され精査目的に当科紹介となった. 胆嚢結石症, 総胆管結石症, 急性膵炎に対する治療歴があった. 腹部造影CTでは, 肝S3に辺縁がリング状に造影され, 内部が低吸収を呈する境界不明瞭な3cm大の腫瘍性病変を認めた. 発熱などの炎症症状なく, 臨床経過および画像検査所見より肝内胆管癌と術前診断し, 肝外側区域切除術を施行した. 切除標本では, 境界明瞭な淡黄白色の硬い腫瘤を認め, 肉眼的にも肝内胆管癌が疑われた. しかし, 組織検査所見では腫瘍細胞は認めず, 好中球浸潤の目立つ急性・慢性炎症性細胞と線維芽細胞, 線維化からなるmicroabscessの像であり, granulomatous abscessと診断した. 胆道の手術既往がある症例などには肝内胆管癌の鑑別診断に肝granulomatous abscessも考慮されるべきと思われた.

  • Open Access

    A small interfering RNA targeting proteinase‐activated receptor‐2 is effective in suppression of tumor growth in a Panc1 xenograft model

    by Kentaro Iwaki, Kohei Shibata, Masayuki Ohta, Yuichi Endo, Hiroki Uchida, Masayuki Tominaga, Ryoki Okunaga, Seiichiro Kai, Seigo Kitano

    Proteinase‐activated receptor‐2 (PAR‐2), which is a G protein‐coupled receptor, is activated in inflammatory processes and cell proliferation. We previously demonstrated that an anti‐PAR‐2 antibody suppresses proliferation of human pancreatic cellsin vitro. However, there have been no studies of PAR‐2 signaling pathwaysin vivo. The aim of this study was to determine whether blockade of PAR‐2 by RNA interference influences pancreatic tumor growth. We originally constructed small interfering RNAs (siRNAs) targeting humanPAR‐2, and performed cell proliferation assays of Panc1 human pancreatic cancer cell line with these siRNAs. Intratumoral treatment with these PAR‐2 siRNAs and atelocollagen was also performed in a xenograft model with nude mice and Panc1 cells. siRNAs against humanPAR‐2inhibited proliferation of Panc1 cells, whereas control scramble siRNAs had no effect on proliferation. The PAR‐2 siRNAs dramatically suppressed tumor growth in the xenograft model. PAR‐2‐specific siRNA inhibited growth of human pancreatic cancer cells bothin vitroandin vivo. Blockade of PAR‐2 signaling by siRNA may be a novel strategy to treat pancreatic cancer.


    • 1 June 2007
      • Vol. 34  (6) , 957-9

    [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].

    by Xiao Yan Fan, Hiroki Uchida, Kentaro Iwaki, Seiichiro Kai, Kohei Shibata, Masayuki Ohta, Seigo Kitano

    Systemic chemotherapy has not seen widespread use in the treatment for hepatocellular carcinoma (HCC). Recently, it was reported that combination treatment of 5-fluorouracil (5-FU) and interferon (IFN)-alpha was effective for non-resectable HCC. The effect of 5-FU treatment is influenced by the activities of pyrimidine catabolic enzymes. The aim of this study was to investigate which IFN-alphais most effective in combination therapy via downregulation of dihydropyrimidine dehydrogenase (DPD). Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF). At the same time,DPD mRNA levels were quantified by real-time polymerase chain reaction. 5-FU alone but not all the IFNs showed anti-cancer effects, and the combination of each IFN +5-FU had a greater anti-cancer effect than 5-FU alone. C-IFN +5-FU most effectively prevented cancer cell proliferation (p < 0.05). Also, the combination of C-IFN +5-FU most downregulated DPD mRNA expression. The combination of each IFN-alpha +5-FU showed anti-cancer effects for HCC via downregulation of DPD. C-IFN may be most effective in the combination therapy of IFN-alpha +5-FU for HCC.